MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

3.260 +0.080 (+2.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN)
From Levi & Korsinsky, LLP
Via Business Wire
Myriad Genetics (NASDAQ:MYGN) Plunges 26% After Fiscal Q2 Revenue and EPS Miss, Slashes Full-Year Guidance ↗
Via Chartmill
News headline image
Myriad Genetics Q2 Earnings Call Highlights ↗
Myriad Genetics (NASDAQ:MYGN) reported second-quarter 2026 revenue of $190.7 million, down 11% from a year earlier, as a 1% decline in total test volume and a 9% decrease in revenue per test weighed on... 
Via MarketBeat
Topics Artificial Intelligence Earnings
Top movers in Friday's session ↗
Via Chartmill
News headline image
Why Myriad Genetics (MYGN) Shares Are Falling Today
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 46.1% in the afternoon session after the company reported disappointing s... 
Via StockStory
Topics Artificial Intelligence
Top stock movements in today's session. ↗
Via Chartmill
Gapping stocks in Friday's session ↗
Via Chartmill
Friday's pre-market session: top gainers and losers ↗
Via Chartmill
Thursday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Myriad Genetics (NASDAQ:MYGN) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 28.6%
Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q2 CY2026, with sales falling 10.5% year on year to ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics (MYGN) Reports Q2: Everything You Need To Know Ahead Of Earnings
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting earnings this Thursday after market hours. Here’s what you need to know. Myriad Genet... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Unprofitable Stocks That Fall Short
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv... 
Via StockStory
News headline image
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
3 Reasons MYGN is Risky and 1 Stock to Buy Instead
Myriad Genetics has been treading water for the past six months, recording a small loss of 3.6% while holding steady at $5.66. The stock also fell short of t... 
Via StockStory
News headline image
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen
The only lab test to run four prenatal genetic screens simultaneously as early as eight weeks gestation 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
Findings from 14 studies involving more than 8,000 patients show Prolaris adds insight beyond conventional clinical risk categories 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
1 Unpopular Stock That Should Get More Attention and 2 We Find Risky
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
Via StockStory
News headline image
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers. Over th... 
Via StockStory
Topics Artificial Intelligence
News headline image
Why Is Myriad Genetics (MYGN) Stock Rocketing Higher Today
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 9.2% in the morning session after the company expanded the availability... 
Via StockStory
News headline image
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
1 Cash-Burning Stock with Promising Prospects and 2 Facing Headwinds
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses... 
Via StockStory
Topics Bankruptcy
News headline image
3 High-Flying Stocks We’re Skeptical Of
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo... 
Via StockStory
News headline image
Myriad Genetics Names Raj Jampa as New Chief Technology Officer
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
Six ASCO abstracts and an industry expert theater session underscore Myriad’s leadership in the cancer care continuum 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
New PATHOMIQ AI integration helps clinicians tailor active surveillance with greater confidence 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
1 Unprofitable Stock to Consider Right Now and 2 We Turn Down
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th... 
Via StockStory
Topics Energy
News headline image
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
The Netflix star partners with Myriad Genetics to tell her BRCA1 story and why she wants everyone to know about hereditary cancer testing 
From Myriad Genetics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story